Frontiers in Clinical Diabetes and Healthcare (May 2023)

Hyperinsulinemia: an early biomarker of metabolic dysfunction

  • Rama A. Vaidya,
  • Sharvari Desai,
  • Panchali Moitra,
  • Sheryl Salis,
  • Shubhada Agashe,
  • Rekha Battalwar,
  • Anushree Mehta,
  • Jagmeet Madan,
  • Soumik Kalita,
  • Shobha A. Udipi,
  • Ashok B. Vaidya

DOI
https://doi.org/10.3389/fcdhc.2023.1159664
Journal volume & issue
Vol. 4

Abstract

Read online

IntroductionHyperinsulinemia in the absence of impaired glucose tolerance and normal HbA1c is considered indicative of pre-diabetes. Very few Indian studies have focused on hyperinsulinemia particularly in young adults. The present study aimed to determine whether hyperinsulinemia may be present despite HbA1c being normal.MethodsThis was a cross–sectional study conducted on adolescents and young adults aged 16-25 years living in Mumbai, India. The participants attended various academic institutions and were those who underwent screening as the first step of a clinical trial for studying the efficacy of almond intake in prediabetes.ResultsAmong this young population (n=1313), 4.2% (n=55) of the participants were found to be prediabetic (ADA criteria) and 19.7% of them had HbA1c levels between 5.7%-6.4%. However, almost, 30.5% had hyperinsulinemia inspite of normal blood glucose levels and normal HbA1c. Among those with HbA1c<5.7 (n=533), 10.5% (n=56) participants had fasting insulin>15 mIU/L and a higher percentage (39.4%, n=260) had stimulated insulin above 80 mIU/L. These participants had higher mean anthropometric markers than those with normal fasting and/or stimulated insulin.ConclusionHyperinsulinaemia in the absence of impaired glucose tolerance and normal HbA1c may provide a much earlier indicator of detection for risk of metabolic disease and progression to metabolic syndrome and diabetes mellitus.

Keywords